JMJD5 promotes chemotherapy sensitivity of cisplatin in NSCLC by enhancing DNA damage
{{output}}
Background: Platinum-based chemotherapy remains a cornerstone in the treatment of advanced non-small cell lung cancer (NSCLC), yet its efficacy is frequently limited by drug resistance. JMJD5 (Jumonji Domain-Containing Protein 5)... ...
